Precision Oncology Sector Sees Transformation with Biomarker-Driven Therapies and Immunotherapies.

Wednesday, Nov 19, 2025 9:51 am ET1min read
ALXO--
ERAS--
IMRX--
ONCY--

The precision oncology sector is experiencing significant growth, with a market value of $106.21 billion in 2025 and an 11% compound annual rate. Biomarker-driven therapies and platform immunotherapies are transforming cancer treatment paradigms, particularly for historically difficult cancers. Companies like Oncolytics Biotech, ALX Oncology, Erasca, Immuneering, and Prelude Therapeutics are leading the charge with targeted therapies for gastrointestinal, blood, and solid tumor cancers.

Stay ahead of the market.

Get curated U.S. market news, insights and key dates delivered to your inbox.

Comments



Add a public comment...
No comments

No comments yet